Taken together, these studies suggest that targeting the CXCR4/CXCL12 pathway results in decreased prostate progenitor survival in vitro and in vivo in androgen refractory cancer cell lines and potentially could be of therapeutic value against advanced prostate cancers. Here, CXCL12 is linked to cancer.